Trial Profile
A retrospective study of certolizumab pegol in patients with refractory uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- 17 Jun 2017 Results (n=13), presented at the 18th Annual Congress of the European League Against Rheumatism
- 24 Jan 2017 New trial record